LOGIN
Alendronate is superior to alfacalcidol in preventing glucocorticoid-induced bone loss
August 2013
Alendronate is superior to alfacalcidol in preventing glucocorticoid-induced bone loss
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Alendronate or Alfacalcidol in Glucocorticoid-Induced Osteoporosis
N Engl J Med. 2006 Aug 17;355(7):675-84Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
201 patients with a rheumatic disease who were starting daily doses of glucocorticoids were randomized to receive 10 mg of alendronate and a placebo capsule of alfacalcidol daily or 1 ug of alfacalcidol and a placebo tablet of alendronate daily. At 18 months, the lumbar spine bone mineral density of patients who received alendronate had increased significantly more than that of the patients who re...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.